Legislation, policies, appropriations, and regulatory relief to support the development, construction, and operation of new U.S.-based active pharmaceutical ingredient (API) manufacturing facilities; initiatives to strengthen domestic API supply chains and reduce reliance on foreign-sourced APIs; FDA regulatory streamlining and expedited review for new API manufacturing plants; federal grant, tax incentive, and contracting mechanisms to increase private investment in domestic API production; implementation of Executive Order(s) or federal policy aimed at boosting U.S.-based pharmaceutical manufacturing; relevant provisions of H.R. 1405 (Enhancing Domestic Drug Manufacturing Act), S. 257 (Promoting Resilient Supply Chains Act of 2025), the RAPID Reserve Act, and other pending bills and actions to advance U.S. pharmaceutical supply chain resilience and capacity.
2025 · 3rd Quarter (July 1 - Sep 30)
SENTINEL API GROUP, INC.
Filed by EXECUTIVE STRATEGIES, LTD. CO..
Open official filingSource-reported fields
Filing overview
- Type
- 3rd Quarter - Report
- Posted
- Oct 20, 2025
- Income
- $20,000.00
- Expenses
- Not reported
- Registrant
- EXECUTIVE STRATEGIES, LTD. CO.
- Client
- SENTINEL API GROUP, INC.
- Filing UUID
- 04672631-1ba1-4405-856b-5e0fcb9968ba
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.